Wataru Hayashi

Wataru Hayashi

Auto-generated profile, based on publicly available information

Wataru Hayashi

Antimicrobial Resistance Research Center, National Institute of Infectious Diseases, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Veterinary Microbiology
Verified
Journal Article
Closed access
YMYoshihiko Maeyama
Yoshihiko Maeyama
YTYui Taniguchi
Yui Taniguchi
WHWataru Hayashi
Wataru Hayashi
YOYusuke Ohsaki
Yusuke Ohsaki
SOShunsuke Osaka
Shunsuke Osaka
NNNoriyuki Nagano
Noriyuki Nagano

15 November 2019 in Applied and Environmental Microbiology
Verified
Journal Article
Closed access
PDF file
WHWataru Hayashi
Wataru Hayashi
HTHayato Tanaka
Hayato Tanaka
YTYui Taniguchi
Yui Taniguchi
MIMasaki Iimura
Masaki Iimura
ESEiji Soga
Eiji Soga
NNNoriyuki Nagano
Noriyuki Nagano
Colistin is considered a last-line therapeutic option in severe infections due to multidrug-resistant Gram-negative bacteria, in particular carbapenemase-producing Enterobacteriaceae and multidrug-resistant Acinetobacter baumannii . An increasing prevalence of mcr genes in diverse Enterobacteriaceae species, mainly Escherichia coli and Klebsiella pneumoniae from humans and food animals, has become a significant concern to public health all over the world. In Japan, mcr genes have so far been detected in food animals, raw meat, wastewater, and human clinical samples. This study reports the copresence of mcr-1 and avian pathogenic E. coli (APEC)-associated virulence genes in five of seven E. coli isolates recovered from aquatic environments in Japan. Our study highlights the importance and urgency of action to reduce environmental contamination by mcr genes that may likely occur due to exposure to untreated wastewater through combined sewer overflow by recent unusual weather.

2 May 2024 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
HYHirokazu Yano
Hirokazu Yano
WHWataru Hayashi
Wataru Hayashi
SKSayoko Kawakami
Sayoko Kawakami
SASadao Aoki
Sadao Aoki
EAEiko Anzai
Eiko Anzai
MSMotoyuki Sugai
Motoyuki Sugai
Japan is a country with an approximate 10% prevalence rate of carbapenem-resistant Pseudomonas aeruginosa (CRPA). Currently, a comprehensive overview of the genotype and phenotype patterns of CRPA in Japan is lacking. Herein, we conducted genome sequencing and quantitative antimicrobial susceptibility testing for 382 meropenem-resistant CRPA isolates that were collected from 78 hospitals across Japan from 2019 to 2020. CRPA exhibited susceptibility rates of 52.9%, 26.4%, and 88.0% against piperacillin–tazobactam, ciprofloxacin, and amikacin, respectively, whereas 27.7% of CRPA isolates was classified as difficult-to-treat resistance P. aeruginosa . Of the 148 sequence types detected, ST274 (9.7%) was predominant, followed by ST235 (7.6%). The proportion of urine isolates in ST235 was higher than that in other STs ( P = 0.0056, χ 2 test). Only 4.1% of CRPA isolates carried the carbapenemase genes: bla GES (2) and bla IMP (13). One ST235 isolate carried the novel bla IMP variant bla IMP-98 in the chromosome. Regarding chromosomal mutations, 87.1% of CRPA isolates possessed inactivating or other resistance mutations in oprD , and 28.8% showed mutations in the regulatory genes ( mexR , nalC , and nalD ) for the MexAB-OprM efflux pump. Additionally, 4.7% of CRPA isolates carried a resistance mutation in the PBP3-encoding gene ftsI . The findings from this study and other surveillance studies collectively demonstrate that CRPA exhibits marked genetic diversity and that its multidrug resistance in Japan is less prevailed than in other regions. This study contributes a valuable data set that addresses a gap in genotype/phenotype information regarding CRPA in the Asia–Pacific region, where the epidemiological background markedly differs between regions.

1 November 2018 in International Journal of Food Microbiology
Verified
Journal Article
Closed access
WHWataru Hayashi
Wataru Hayashi
YOYusuke Ohsaki
Yusuke Ohsaki
YTYui Taniguchi
Yui Taniguchi
SKShota Koide
Shota Koide
KKKumiko Kawamura
Kumiko Kawamura
NNNoriyuki Nagano
Noriyuki Nagano

22 May 2024 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
SKShizuo Kayama
Shizuo Kayama
SKSayoko Kawakami
Sayoko Kawakami
KKKohei Kondo
Kohei Kondo
NKNorikazu Kitamura
Norikazu Kitamura
LYLiansheng Yu
Liansheng Yu
MSMotoyuki Sugai
Motoyuki Sugai
The treatment options available for infections caused by multidrug-resistant Gram-negative pathogens are often limited. Cefiderocol (CFDC) is a novel siderophore cephalosporin that exhibits activity against these pathogens. Several studies have reported the in vitro activity of CFDC against isolates from Europe, the United States, and China, but the activity against carbapenem-resistant bacteria with IMP-type carbapenemase has not been extensively studied. We, therefore, studied the in vitro activities of CFDC against carbapenem-resistant bacteria with available genomic backgrounds based on whole-genome sequencing (WGS) in Japan, where the IMP-type is the predominant carbapenemase produced by Gram-negative rods. We selected 603 isolates (528 Enterobacterales, 18 Pseudomonas aeruginosa, and 57 Acinetobacter spp.) from a collection of Gram-negative clinical isolates collected during a Japan Antimicrobial Resistance Bacterial Surveillance program and evaluated the antimicrobial activities of CFDC, ceftolozane/tazobactam (CTLZ/TAZ), imipenem-relebactam (IPM/REL), and ceftazidime/avibactam (CAZ/AVI) against carbapenemase-producing Enterobacterales, carbapenemase-non-producing meropenem-non-susceptible Enterobacterales, and carbapenemase-producing nonfermentative bacteria. Among these, 97.7% of carbapenemase-producing Enterobacterales (99.2% of IMP-type carbapenemase-producing Enterobacterales), 100% of carbapenemase-producing P. aeruginosa, and 91.2% of carbapenemase-producing Acinetobacter spp. were susceptible to CFDC, showing better antimicrobial activity than the other antimicrobial agents evaluated in this study. CFDC was highly effective against class A-, B-, and D β-lactamase-harbouring isolates when compared to the other antimicrobial agents. In addition, the relationship between CFDC resistance and three genetic factors involved in resistance was discussed. This is the first large-scale study to systematically demonstrate the efficacy of CFDC against IMP-type carbapenemase-producing strains with known genomic backgrounds.

1 January 2017 in Japanese Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
YOYusuke Ohsaki
Yusuke Ohsaki
WHWataru Hayashi
Wataru Hayashi
SSSatomi Saito
Satomi Saito
SOShunsuke Osaka
Shunsuke Osaka
YTYui Taniguchi
Yui Taniguchi
NNNoriyuki Nagano
Noriyuki Nagano
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies